{"contentid": 487931, "importid": NaN, "name": "Phase II failure prompts change of track for luvadaxistat", "introduction": "San Diego\u00e2\u0080\u0099s Neurocrine Biosciences has been dealt a blow by negative results from the Phase II INTERACT study of schizophrenia candidate luvadaxistat.", "content": "<p>San Diego&rsquo;s Neurocrine Biosciences (Nasdaq: NBIX) has been dealt a blow by negative results from the Phase II INTERACT study of schizophrenia candidate luvadaxistat.</p>\n<p>Shares in the firm slumped 7% on Tuesday, following the announcement that the primary efficacy endpoint of the trial had not been met.</p>\n<p>In a statement, Neurocrine said the study did meet secondary endpoints of cognitive assessment, and that these would &ldquo;merit further clinical evaluation.&rdquo;</p>\n<p>The candidate is under co-development with Japan&rsquo;s largest drugmaker, Takeda Pharmaceutical (TYO: 4502), under the terms of an up to $2 billion deal on CNS disorders agreed in mid-2020.</p>\n<p>The firms are working together to develop and commercialize compounds in Takeda&rsquo;s early-to-mid-stage psychiatry pipeline, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.</p>\n<h2>Luvadaxistat</h2>\n<p>Luvadaxistat is a potential first-in-class oral therapy, a selective inhibitor which targets glutamate, an abundant neurotransmitter in the brain.</p>\n<p>There had been a considerable amount of interest in the approach, which was hoped to provide a new way to combat \"negative symptoms\" of the condition, such as lack of communication and motivation.</p>\n<p>The poor data will further dampen hopes that this new class of drug can achieve that, however, after Concert Pharmaceuticals (Nasdaq: CNCE) announced negative results for its candidate, CTP-692, which employs a similar approach.</p>\n<p>Concert saw its shares fall by around 40% in early February, after it announced a Phase II study of CTP-692 did not meet the primary endpoint or other secondary endpoints.</p>\n<p>Neurocrine does not look ready to drop its program altogether though, stating that the full results from the study would be evaluated in order to determine next steps.</p>\n<p>Chief medical officer Eiry Roberts said the firm was &ldquo;encouraged that secondary endpoints assessing cognitive performance within the trial were met and that treatment emergent adverse events reported were consistent with previous luvadaxistat studies.\"</p>\n<p>He added: \"The totality of the top-line data from this study therefore support further clinical evaluation of luvadaxistat. We plan to work with our partner Takeda as we move forward.\"</p>", "date": "2021-03-03 13:28:00", "meta_title": NaN, "meta_keywords": "luvadaxistat, study, Phase, Neurocrine, candidate, negative, results, schizophrenia, prompts, change, track, failure, dealt, INTERACT, blow, Biosciences", "meta_description": "San Diego\u00e2\u0080\u0099s Neurocrine Biosciences has been dealt a blow by negative results from the Phase II INTERACT study of schizophrenia candidate luvadaxistat.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-03 13:28:19", "updated": "2021-03-03 14:12:55", "access": NaN, "url": "https://www.thepharmaletter.com/article/phase-ii-failure-prompts-change-of-track-for-luvadaxistat", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "neurocrine-big.png", "image2id": "neurocrine-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Neurological", "topic_tag": "Drug Trial, Research", "geography_tag": "Japan, USA", "company_tag": "Neurocrine Biosciences, Takeda", "drug_tag": "luvadaxistat", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-03 13:28:00"}